These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 9885363)
1. A characterization of the coagulant and fibrinolytic profile of human pancreatic carcinoma cells. Kakkar AK; Chinswangwatanakul V; Tebbutt S; Lemoine NR; Williamson RC Haemostasis; 1998; 28(1):1-6. PubMed ID: 9885363 [TBL] [Abstract][Full Text] [Related]
2. Localization of blood coagulation factors in situ in pancreatic carcinoma. Wojtukiewicz MZ; Rucinska M; Zacharski LR; Kozlowski L; Zimnoch L; Piotrowski Z; Kudryk BJ; Kisiel W Thromb Haemost; 2001 Dec; 86(6):1416-20. PubMed ID: 11776308 [TBL] [Abstract][Full Text] [Related]
3. [Activators and inhibitors of blood coagulation and fibrinolysis in the human placenta and myometrium]. Uszyński M Rocz Akad Med Im Juliana Marchlewskiego Bialymst; 1971; 16():159-90. PubMed ID: 5004447 [No Abstract] [Full Text] [Related]
5. Coagulation inhibition and activation in pancreatic cancer. Changes during progress of disease. Lindahl AK; Odegaard OR; Sandset PM; Harbitz TB Cancer; 1992 Oct; 70(8):2067-72. PubMed ID: 1394036 [TBL] [Abstract][Full Text] [Related]
6. [Fibrinolytic activity and effect of anti-fibrinolytic agents on the growth of cloned cell lines in vitro (author's transl)]. Sekiya S; Kizawa I; Takamizawa H Nihon Sanka Fujinka Gakkai Zasshi; 1980 Jul; 32(7):868-72. PubMed ID: 7240865 [TBL] [Abstract][Full Text] [Related]
7. Coagulation factors and components of the fibrinolytic system in lymph and blood in dogs. Leandoer L; Bergentz SE; Nilsson IM Thromb Diath Haemorrh; 1968 Mar; 19(1):129-35. PubMed ID: 5652223 [No Abstract] [Full Text] [Related]
8. The role of tissue factor pathway inhibitor in tumor growth and metastasis. Amirkhosravi A; Meyer T; Amaya M; Davila M; Mousa SA; Robson T; Francis JL Semin Thromb Hemost; 2007 Oct; 33(7):643-52. PubMed ID: 18000790 [TBL] [Abstract][Full Text] [Related]
9. [Fibrinolytic homeostasis in pregnancy. I. Quantitative relations between pro- and anti-fibrinolytic factors. Clinical and experimental study]. Giordano G Minerva Ginecol; 1969 Jul; 21(14):888-92. PubMed ID: 4249426 [No Abstract] [Full Text] [Related]
10. Coagulation factors and fibrinolytic proteins in menstrual fluid collected from normal and menorrhagic women. Rees MC; Cederholm-Williams SA; Turnbull AC Br J Obstet Gynaecol; 1985 Nov; 92(11):1164-8. PubMed ID: 2415154 [TBL] [Abstract][Full Text] [Related]
11. Aqueous extract from Brownea grandiceps flowers with effect on coagulation and fibrinolytic system. Pereira B; Brazón J J Ethnopharmacol; 2015 Feb; 160():6-13. PubMed ID: 25460592 [TBL] [Abstract][Full Text] [Related]
12. [On activators and inhibitors of fibrinolysis in the amniotic fluid and in extracts of the placenta, decidua and myometrium of interrupted and normally terminated pregnancies]. Slunský R Folia Haematol Int Mag Klin Morphol Blutforsch; 1967; 88(2):236-43. PubMed ID: 4174664 [No Abstract] [Full Text] [Related]
13. Imbalance of plasminogen activator inhibitor-I/ tissue plasminogen activator and tissue factor/tissue factor pathway inhibitor in young Japanese men with myocardial infarction. Saigo M; Abe S; Ogawa M; Yamashita T; Biro S; Minagoe S; Maruyama I; Tei C Thromb Haemost; 2001 Nov; 86(5):1197-203. PubMed ID: 11816707 [TBL] [Abstract][Full Text] [Related]
14. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways. Munkvad S Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763 [TBL] [Abstract][Full Text] [Related]
15. Separation and characterization of two fibrinolytic inhibitors from human placenta. Uszynski M; Abildgaard U Thromb Diath Haemorrh; 1971 Jun; 25(3):580-9. PubMed ID: 4998018 [No Abstract] [Full Text] [Related]
16. Effect of resection of localized pancreaticobiliary adenocarcinoma on angiogenic markers and tissue factor related pro-thrombotic and pro-angiogenic activity. Echrish HH; Xiao Y; Madden LA; Allgar V; Cooke J; Wedgwood K; Dasgupta D; Greenman J; Maraveyas A Thromb Res; 2014 Aug; 134(2):479-87. PubMed ID: 24929839 [TBL] [Abstract][Full Text] [Related]
17. Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis. Kaikita K; Takeya M; Ogawa H; Suefuji H; Yasue H; Takahashi K J Pathol; 1999 Jun; 188(2):180-8. PubMed ID: 10398162 [TBL] [Abstract][Full Text] [Related]
18. [On the development of blood coagulation disorders in pregnancy interruption. VI]. Slunský R Z Geburtshilfe Gynakol; 1967 May; 167(1):42-50. PubMed ID: 5586021 [No Abstract] [Full Text] [Related]
19. Tissue factor pathway inhibitor on circulating microparticles in acute myocardial infarction. Steppich B; Mattisek C; Sobczyk D; Kastrati A; Schömig A; Ott I Thromb Haemost; 2005 Jan; 93(1):35-9. PubMed ID: 15630488 [TBL] [Abstract][Full Text] [Related]
20. [Significance of factors of coagulation and fibrinolysis in progression of lung cancer]. Nagayama M; Tachibana A; Hayakawa H; Sato A Nihon Kyobu Shikkan Gakkai Zasshi; 1993 Feb; 31(2):180-5. PubMed ID: 8390588 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]